Economic value of resistance-guided gonorrhea treatment: cost-neutrality thresholds for resistance test pricing in the United States

⚕️

This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

Imagine the human body as a bustling city, and the bacteria causing gonorrhea (Neisseria gonorrhoeae) as a group of troublemakers trying to break into the city's defenses. For years, the city has had a few reliable security guards (antibiotics) to catch them. But recently, these troublemakers have started wearing "invisibility cloaks" (resistance), making it harder for the guards to spot and stop them. If we keep using the same old guards who can't see through the cloaks, the troublemakers win, and the city suffers.

This paper is like a financial weather forecast for the city's health budget. It asks a crucial question: "Is it worth buying a high-tech scanner to see the troublemakers' invisibility cloaks before we send out the guards?" This scanner is called a "resistance test."

Here is the breakdown of the study's findings using simple analogies:

1. The Problem: Guessing vs. Knowing

Right now, doctors often have to guess which guard to send. They might send a guard (like Ciprofloxacin) who the troublemakers have already learned to dodge. This leads to:

Failed missions: The infection stays.
Collateral damage: We have to use our "super-guards" (like Ceftriaxone) too often, which makes the troublemakers learn to dodge those, too.
Wasted money: Treating the same person twice or dealing with complications costs a fortune.

2. The Solution: The "Resistance Test"

The study suggests using a test that tells the doctor exactly which "invisibility cloak" the troublemaker is wearing.

If the test says: "They can dodge Guard A," the doctor sends Guard B.
If the test says: "They can dodge both," the doctor uses the Super-Guard immediately.

This strategy is called Resistance-Guided Treatment (RGT). It's like having a GPS that tells you exactly which road is blocked, so you don't waste gas driving down a dead end.

3. The Big Question: How much can we pay for the GPS?

The researchers built a complex computer simulation (a "digital twin" of the US healthcare system) to figure out the price tag. They wanted to know: What is the maximum price we can pay for this test before it stops saving us money?

They looked at three different "GPS models":

Basic Model: Checks for one type of resistance.
Standard Model: Checks for two types.
Super Model: Checks for three types (including a new, experimental drug).

4. The Findings: The "Price Tag" Varies

The study found that the value of the test depends entirely on how many troublemakers are currently wearing invisibility cloaks.

Scenario A: The City is Safe. If almost no troublemakers have cloaks, the test isn't very useful. It's like buying a metal detector when there are no metal objects in the park. The price you should pay for the test is near $0.
Scenario B: The City is Under Attack. If 15% of the troublemakers have cloaks, the test becomes incredibly valuable. It can save the city up to $45 per person by preventing failed treatments and saving our "Super-Guards" for when they are truly needed.
The "Sweet Spot": In a realistic middle-ground scenario (where some troublemakers have cloaks), the study says the test is worth paying $4 to $11 per person. As long as the test costs less than this, the healthcare system actually saves money.

5. The Hidden Bonus: Saving the Future

The study also looked at the "big picture" costs, specifically for a high-risk group (Men who have Sex with Men, or MSM).

The "Super-Guard" Crisis: If we use our last-resort antibiotic too much, the troublemakers will eventually learn to dodge it too. Then, we will have no guards left.
The "New Guard" Bill: Developing a brand-new antibiotic takes billions of dollars and years of work.
The Value of Prevention: By using the test to save our current "Super-Guards," we delay the day when we have to pay billions for a new one. When you factor in this massive future savings, the test becomes worth $35 to $145 per person.

The Bottom Line

Think of this resistance test as an insurance policy.

If you buy a cheap policy ( $4–$ 11), you save money on immediate repairs (treatment failures).
If you consider the cost of rebuilding the whole city if the walls fall (new antibiotic development), that same policy is actually worth a fortune ( $35–$ 145).

Conclusion: The paper argues that even if the test costs a bit of money upfront, it pays for itself by fixing infections faster, saving our best medicines for emergencies, and preventing the need to spend billions on new drugs later. It's a smart investment for the long-term health of the city.

1. Problem Statement

The efficacy of existing therapies for Neisseria gonorrhoeae is increasingly threatened by rising antimicrobial resistance (AMR). The indiscriminate use of antibiotics, particularly last-line agents like ceftriaxone, accelerates the emergence of resistant strains, leading to treatment failures, severe complications, and increased transmission. While Resistance-Guided Treatment (RGT)—tailoring therapy based on specific resistance profiles—offers a potential solution to optimize treatment, reduce inappropriate antibiotic use, and slow resistance emergence, its widespread adoption is hindered by the cost of diagnostic testing. There is a critical lack of data quantifying the economic value of RGT to determine the maximum price point at which these tests remain cost-neutral or cost-saving for the healthcare system.

2. Methodology

The authors developed a comprehensive individual-level stochastic simulation model to evaluate the economic impact of RGT in the United States. Key methodological components include:

Model Scope: The simulation incorporates infection prevalence, symptom status, diagnostic accuracy, local resistance profiles, treatment pathways, and partner management strategies. All costs are adjusted to 2025 USD.
Strategies Evaluated: Three distinct resistance testing strategies were compared against standard empiric treatment:
1. Ciprofloxacin-only (CIP-only): Testing for resistance to ciprofloxacin.
2. Ciprofloxacin + Ceftriaxone: Dual-target testing.
3. Triple-target: A comprehensive test including ciprofloxacin, ceftriaxone, and a novel drug (Drug A).
Economic Dimensions: The study quantified value across three specific metrics:
1. Per-episode direct medical cost savings: Immediate savings from avoiding ineffective treatments and managing complications.
2. System-level costs: Long-term costs attributable to the emergence of ceftriaxone resistance, specifically within the Men who have Sex with Men (MSM) population.
3. Avoided development costs: The economic value of delaying the need for new antibiotic development.
Primary Outcome: The study calculated the cost-neutrality threshold, defined as the maximum per-test price at which the total benefits of RGT equal the costs of the test itself.

3. Key Contributions

Multi-Dimensional Economic Valuation: Unlike previous studies focusing solely on immediate clinical costs, this paper integrates long-term systemic risks (resistance emergence) and macro-economic factors (avoided drug development costs) into the economic model.
Scenario-Based Pricing Thresholds: The study provides specific price thresholds for diagnostic tests under varying resistance scenarios, offering actionable data for policymakers and payers.
MSM-Specific Analysis: It explicitly models the impact of resistance emergence within the MSM population, a key demographic for gonorrhea transmission and resistance spread, to capture the full system-level value of RGT.

4. Results

The simulation yielded significant findings regarding the economic viability of RGT:

Variable Thresholds: The cost-neutrality threshold is highly sensitive to local resistance rates.
- In scenarios with no ceftriaxone resistance, the threshold is near $0.
- At 15% ceftriaxone resistance, the threshold rises to $45/test.
Specific Scenario Estimates:
- Under a scenario of 50% ciprofloxacin resistance and 5% ceftriaxone resistance:
  - The population-weighted threshold for a CIP-only test is $4 (95% Uncertainty Interval [UI]: $3–$ 8).
  - The threshold for a triple-target test is $11 (95% UI: $5–$ 14).
System-Level Value (MSM Focus): When incorporating the long-term costs of ceftriaxone resistance emergence and avoided antibiotic development costs among MSM:
- The total per-test value for a single-target test increases significantly to $35–$ 145.
- The value for a triple-target test ranges from $84–$ 128.
- Note: These higher values depend on whether prescribing practices shift effectively when ceftriaxone resistance reaches 5%.

5. Significance

The study concludes that Resistance-Guided Therapy offers substantial economic benefits across multiple dimensions, even at relatively high diagnostic prices. The findings support the argument that:

Investment Justification: Public and private investment in gonorrhea resistance testing is economically justified, as the long-term savings from delayed resistance and avoided drug development far exceed the cost of the tests.
Policy Implications: Payers and health systems should consider the "system-level" value of diagnostics, not just the immediate episode cost, when setting reimbursement rates for resistance tests.
Strategic Impact: Implementing RGT can improve partner outcomes, significantly delay the emergence of untreatable gonorrhea strains, and enhance the long-term cost-efficiency of gonorrhea management in the United States.